Pataday Once Daily Relief (Olopatadine HCl) Patent Expiration, LOE Window & CMS Spending

Pataday Once Daily Relief (Olopatadine HCl) by Novartis: FDA Orange Book LOE 2032-05-19, 3 AB generics, $1.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN021545 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2032-05-19
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$1.1M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$1.1M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.